References for Cytochrome P450 Drug Interaction Table: 1A2
These pages contain all the literature citations referenced in the Cytochrome P450 Drug Interaction Tables (both the extensive research-oriented table and the concise clinical table). Most of these citations are hyperlinks, which bring up the abstract in the NLM's PubMed database.
Click on the [ PubMed ] link after the drug name to perform a live MedLINE search of articles possibly related to that drug and Cytochrome P450.
Entries are organized by mode of activity (substrate, inhibitor, inducer) within specific isoform. You can quickly branch to a section by clicking on the appropriate link here:
1A2 | 2B6 | 2C8 | 2C19 | 2C9 | 2D6 | 2E1 | 3A457
Use Ctrl-F to find all or part of the name or word for which you are searching.
amitriptyline:
PubMed
Fluvoxamine-tricyclic antidepressant interaction. An accidental
finding.
Bertschy G, Vandel S, Vandel B, Allers G, Volmat R
Eur J Clin Pharmacol 1991;40(1):119-120. [Letter]
caffeine:
PubMed
Determination of urinary metabolites of caffeine for the assessment of
cytochrome P4501A2, xanthine oxidase, and N-acetyltransferase activity in
humans.
Rasmussen BB, Brosen K
Ther
Drug Monit 1996 Jun;18(3):254-262
Assays for CYP1A2 by testing in vivo metabolism of caffeine in humans.
Tang BK, Kalow W
Methods
Enzymol 1996;272:124-131
clomipramine:
PubMed
Fluvoxamine-tricyclic antidepressant interaction. An accidental
finding.
Bertschy G, Vandel S, Vandel B, Allers G, Volmat R
Eur J Clin Pharmacol 1991;40(1):119-120. [Letter]
clozapine:
PubMed
Metabolism and bioactivation of clozapine by human liver in vitro.
Pirmohamed, M., Williams, D., Madden, S., Templeton, E., and Park, B.K
J
Pharmacol Exp Ther 272(3):984-990, 1995
Clozapine disposition covaries with CYP1A2 activity determined by a caffeine
test.
Bertilsson, L., Carrillo, J.A., Dahl, M.-L., Llerena, A., Alm, C., Bondesson,
U., Lindstrom, L., de la Rubia, I.R., Ramos, S., and Benitez, J
Br
J Clin Pharmacol 38:471-473, 1994
cyclobenzaprine:
PubMed
Identification of Human Liver Cytochrome
P450 Isoforms involved in the in vitro metabolism of cyclobenzaprine.
Wang RW, Liu L, Cheng H
Drug
Metab Dispos 1996;24(7):786-791
fluvoxamine:
PubMed
Disposition of fluvoxamine in humans is determined by the polymorphic
CYP2D6 and also by the CYP1A2 activity.
Carillo JA, Dahl M-L, Svennson J-O, Alm C, Rodriguez I, Bertillson L
Clin Pharmacol Ther 1996;60:183-190
estradiol:
PubMed
Differences in the cytochrome P-450 isoenzymes involved in the 2-hydroxylation
of oestradiol and 17alpha-ethinyloestradiol.
Ball, S.E., Forrester, L.M., Wolf, C.R., and Back, D.J
Biochem
J 267:221-226, 1990
haloperidol:
PubMed
Coadministration of fluvoxamine increases serum
concentrations of haloperidol.
Daniel, D.G., Randolph, C., Jaskiw, G., Handel, S., Williams, T.,
Abi-Dargham, A., Shoaf, S., Egan, M., Elkashef, A., Liboff, S., and Linnoila,
M
J
Clin Psychopharmacol 14:340-343, 1994
imipramine:
PubMed
Reappraisal of human CYP isoforms involved in imipramine N-demethylation
and 2-hydroxylation: a study using microsomes obtained from putative extensive
and poor metabolizers of S-mephenytoin and eleven recombinant human CYPs.
Koyama E, Chiba K, Tani M, Ishizaki T
J
Pharmacol Exp Ther 1997 Jun;281(3):1199-1210
Major pathway of imipramine metabolism is catalyzed by cytochromes P-450
1A2 and P-450 3A4 in human liver.
Lemoine A, Gautier JC, Azoulay D, Kiffel L, Belloc C, Guengerich FP, Maurel
P, Beaune P, Leroux JP
Mol
Pharmacol 1993 May;43(5):827-832
mexiletine:
PubMed
CYP1A2 is the major enzyme involved in the metabolism of mexillitene in man.
Abolfathi Z, Pakdel H, Beaune P, Turgeon J
Clin Pharmacol Ther 1995;57(2):215 Abst.
Ciprofloxacin decreases mexillitene (mex) clearance in smokers and
non-smokers.
Labbe L, Lefez C, Gilbert M, O'Hara G, Turgeon J
Clin Pharmacol Ther 1995;57:210 Abst.
naproxen:
PubMed
Cytochromes P450, 1A2, and 2C9 are responsible for the human hepatic
O-demethylation of R- and S-naproxen.
Miners JO, Coulter S, Tukey RH, Veronese ME, Birkett DJ
Biochem
Pharmacol 1996 Apr 26;51(8):1003-1008
olanzapine
PubMed
ondansetron (in
part):
PubMed
Multiple forms of cytochrome P450 are involved in the metabolism of
ondansetron in humans.
Dixon CM, Colthup PV, Serabjit-Singh CJ, Kerr BM, Boehlert CC, Park GR, Tarbit
MH
Drug
Metab Dispos 1995 Nov;23(11):1225-1230
phenacetin:
PubMed
Specificity of substrate and inhibitor probes for human cytochromes P450
1A1 and 1A2.
Tassaneeyakul W, Birkett DJ, Veronese ME, McManus ME, Tukey RH, Quattrochi
LC, Gelboin HV, Miners JO
J
Pharmacol Exp Ther 1993 Apr;265(1):401-407
propranolol:
PubMed
Selective induction of propranolol metabolism by smoking: Additional effects
on renal clearance of metabolites.
Walle, U.K., Walle, T., Cowart, T.D., Conradi, E.C., and Gaffney, T.E
J.
of Pharm. & Exp. Ther. 241:928-933, 1987
Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic properties,
and therapeutic efficacy in depressive illness.
Benfield, P and Ward A
Drugs
1986;32:313-334
[Fluvoxamine is a potent inhibitor of propranolol metabolism in vivo.]
riluzole:
PubMed
Involvement of human CYP1A isoenzymes in the metabolism and drug interactions
of riluzole in vitro.
Sanderink GJ, Bournique B, Stevens J, Petry M, Martinet M
J
Pharmacol Exp Ther 1997 Sep;282(3):1465-1472
ropivacaine:
PubMed
Metabolism of ropivacaine in humans is mediated by CYP1A2 and to
a minor extent by CYP3A4: an interaction study with fluvoxamine and ketoconazole
as in vivo inhibitors.
Arlander E, Ekstrom G, Alm C, Carrillo JA, Bielenstein M, Bottiger Y, Bertilsson
L, Gustafsson LL
Clin
Pharmacol Ther 1998 Nov;64(5):484-91
tacrine:
PubMed
Determination of human hepatic cytochrome P450 1A2 activity in vitro:
use of tacrine as an isozyme-specific probe.
Spaldin V, Madden S, Adams DA, Edwards RJ, Davies DS, Park BK
Drug
Metab Dispos 1995;23(9):929-934
theophylline:
PubMed
Metabolism of theophylline by cDNA-expressed human cytochromes
P450.
Ha HR, Chen J, Freiburghaus AU, Follath F
Br J Clin Pharmacol 1995;39:321-326
tizanidine
PubMed
Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism.
Granfors MT, Backman JT, Neuvonen M, Neuvonen PJ.
Clin Pharmacol Ther. 2004 Dec;76(6):598-606
Fluvoxamine drastically increases concentrations and effects of tizanidine: a potentially hazardous interaction.
Granfors MT, Backman JT, Neuvonen M, Ahonen J, Neuvonen PJ.
Clin Pharmacol Ther. 2004 Apr;75(4):331-41
verapamil:
PubMed
The effect of three different oral doses of verapamil on the disposition
of theophylline.
Stringer KA, Mallet J, Clarke M, Lindenfeld JA
Eur
J Clin Pharmacol 1992;43(1):35-38
Verapamil-induced inhibition of theophylline elimination in healthy
humans.
Nielsen-Kudsk JE, Buhl JS, Johannessen AC
Pharmacol
Toxicol 1990 Feb;66(2):101-103
warfarin:
PubMed
zileuton:
PubMed
Identification of the human liver cytochrome P450 enzymes involved
in the metabolism of zileuton (ABT-077) and its N-dehydroxylated metabolite,
Abbott-66193.
Machinist JM, Mayer MD, Shet MS, Ferrero JL, Rodrigues AD
Drug
Metab Dispos. 1995 Oct; 23(10): 1163-1174
zolmitriptan:
Pubmed
Determination of the human cytochrome P450 isoforms involved in the metabolism
of zolmitriptan.
Wild MJ, McKillop D, Butters CJ
Xenobiotica.
1999 Aug;29(8):847-57
| » CIMETIDINE |
[ PubMed ] |
| Article | The effect of cimetidine on dextromethorphan O-demethylase activity of human liver microsomes and recombinant CYP2D6. |
| Authors | Madeira M, Levine M, Chang TK, Mirfazaelian A, Bellward GD. |
| Link to Abstract | Drug Metab Dispos. 2004 Apr;32(4):460-7.
|
| Article | Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists. |
| Authors | Martínez C, Albet C, Agúndez JA, Herrero E, Carrillo JA, Márquez M, Benítez J, Ortiz JA. |
| Link to Abstract | Clin Pharmacol Ther. 1999 Apr;65(4):369-76.
|
| Article | Imipramine-cimetidine interaction: impairment of clearance and enhanced absolute bioavailability. |
| Authors | Abernethy DR, Greenblatt DJ, Shader RI. |
| Link to Abstract | J Pharmacol Exp Ther. 1984 Jun;229(3):702-5.
|
| Info | www.rxlist.com |
| » FLUVOXAMINE |
[ PubMed ] |
| Article | Fluvoxamine is a potent inhibitor of cytochrome P4501A2. |
| Authors | Brosen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S. |
| Link to Abstract | Biochem Pharmacol 1993 Mar 24;45(6):1211-1214.
|
| Article | Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2. |
| Authors | Ball SE, Ahern D, Scatina J, Kao J. |
| Link to Abstract | Br J Clin Pharmacol. 1997 Jun;43(6):619-26.
|
| Article | Dose-dependent alternations in the pharmacokinetics of olanzapine during coadministration of fluvoxamine in patients with schizophrenia. |
| Authors | Chiu CC, Lane HY, Huang MC, Liu HC, Jann MW, Hon YY, Chang WH, Lu ML. |
| Link to Abstract | J Clin Pharmacol. 2004 Dec;44(12):1385-90.
|
| Article | Cytochrome P450 1A2 is a major determinant of lidocaine metabolism in vivo: effects of liver function. |
| Authors | Orlando R, Piccoli P, De Martin S, Padrini R, Floreani M, Palatini P. |
| Link to Abstract | Clin Pharmacol Ther. 2004 Jan;75(1):80-8.
|
| Article | Fluvoxamine-theophylline interaction: gap between in vitro and in vivo inhibition constants toward cytochrome P4501A2. |
| Authors | Yao C, Kunze KL, Kharasch ED, Wang Y, Trager WF, Ragueneau I, Levy RH. |
| Link to Abstract | Clin Pharmacol Ther. 2001 Nov;70(5):415-24.
|
| Article | Effect of fluvoxamine on the pharmacokinetics of mexiletine in healthy Japanese men. |
| Authors | Kusumoto M, Ueno K, Oda A, Takeda K, Mashimo K, Takaya K, Fujimura Y, Nishihori T, Tanaka K. |
| Link to Abstract | Clin Pharmacol Ther. 2001 Mar;69(3):104-7.
|
| Article | Fluvoxamine is a potent inhibitor of tacrine metabolism in vivo. |
| Authors | Larsen JT, Hansen LL, Spigset O, Brøsen K. |
| Link to Abstract | Eur J Clin Pharmacol. 1999 Jul;55(5):375-82.
|
| Article | Influence of the CYP1A2 inhibitor fluvoxamine on tacrine pharmacokinetics in humans. |
| Authors | Becquemont L, Ragueneau I, Le Bot MA, Riche C, Funck-Brentano C, Jaillon P. |
| Link to Abstract | Clin Pharmacol Ther. 1997 Jun;61(6):619-27.
|
| Info | www.rxlist.com |
furafylline:
PubMed
Furafylline is a potent and selective inhibitor
of P4501A2 in man.
Sesardic D, Boobis AR, Murray BP, Murray S, Segura J, de la Torre R, Davies
DS
Br
J Clin Pharmacol 1990;29:651-663
interferon:
PubMed
Regulation of hepatic cytochrome P-450 during
infectious disease
Renton KW, Knickle LC
Can
J Physiol Pharmacol 1990 Jun;68(6):777-781
methoxsalen:
PubMed
mibefradil:
PubMed
Metabolism of the calcium antagonist, mibefradil (POSICOR,Ro40-5967).
Part III. Comparative pharmacokinetics of mibefradil and its major metabolites
in rat, marmoset, cynomolgus monkey and man.
Wiltshire HR, Sutton BM, Heeps G, Betty AM, Angus DW, Harris SR, Worth E,
Welker HA
Xenobiotica
1997 Jun;27(6):557-571
ticlopidine:
PubMed
Ticlopidine-theophylline interaction.
Colli A, Buccino G, Cocciollo M, Parravicini R, Elli GM, Scaltrini G
Clin
Pharmacol Ther 1987; 41: 358-362
broccoli:
PubMed
brussel sprouts:
PubMed
char-grilled meat:
PubMed
Effects of a chargrilled meat diet on expression of CYP3A, CYP1A, and
P-glycoprotein levels in healthy volunteers.
Fontana RJ, Lown KS, Paine MF, Fortlage L, Santella RM, Felton JS, Knize
MG, Greenberg A, Watkins PB
Gastroenterology
1999 Jul;117(1):89-98
insulin:
PubMed
Hyperinsulinemia causes a preferential increase in hepatic P4501A2
activity.
Barnett CR, Wilson J, Wolf CR, Flatt PR, Ioannides C
Biochem
Pharmacol 1992;43(6):1255-61
methyl cholanthrene:
PubMed
modafinil:
Info
PubMed
In vitro inhibition and induction of human hepatic cytochrome P450 enzymes
by modafinil.
Robertson P, DeCory HH, Madan A, Parkinson
A.
Drug
Metab Dispos 2000 Jun;28(6):664-71
nafcillin:
PubMed
beta-naphthoflavone:
PubMed
omeprazole:
PubMed
tobacco:
PubMed
Effect of smoking on caffeine clearance.
Parsons WD, Neims AH
Clin
pharmacol Ther 1978;24(1):40-45
Assessment of the cytochrome P-448 dependent liver enzyme system by a
caffeine breath test.
Wietholz H, Voegelin M, Arnaud MJ, Bircher J, Preisig R
Eur
J Clin Pharmacol 1981;21:53-59
|